AcelRx Pharmaceuticals (NASDAQ:ACRX) Receives “Outperform” Rating from Credit Suisse Group

Share on StockTwits

Credit Suisse Group reaffirmed their outperform rating on shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) in a research note published on Wednesday, Briefing.com Automated Import reports.

A number of other equities research analysts also recently weighed in on the company. ValuEngine upgraded VESTAS WIND SYS/ADR from a hold rating to a buy rating in a research report on Thursday, May 9th. B. Riley restated a buy rating on shares of Champion Iron in a research report on Wednesday, April 24th. LADENBURG THALM/SH SH restated a buy rating on shares of Paratek Pharmaceuticals in a research report on Thursday, May 9th. BidaskClub downgraded Zai Lab from a hold rating to a sell rating in a research report on Wednesday, May 1st. Finally, Zacks Investment Research upgraded DLH from a sell rating to a hold rating in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $7.47.

Shares of ACRX stock traded down $0.09 on Wednesday, reaching $2.78. The company’s stock had a trading volume of 1,297,033 shares, compared to its average volume of 1,904,125. The company has a debt-to-equity ratio of 0.79, a current ratio of 5.03 and a quick ratio of 4.91. AcelRx Pharmaceuticals has a 12-month low of $1.99 and a 12-month high of $5.05. The firm has a market cap of $220.17 million, a P/E ratio of -3.43 and a beta of 2.24. The company has a 50 day simple moving average of $2.46.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.85 million. On average, analysts predict that AcelRx Pharmaceuticals will post -0.84 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACRX. BlackRock Inc. increased its holdings in shares of AcelRx Pharmaceuticals by 196.6% in the fourth quarter. BlackRock Inc. now owns 2,331,736 shares of the specialty pharmaceutical company’s stock worth $5,386,000 after buying an additional 1,545,702 shares during the period. Two Sigma Advisers LP purchased a new position in shares of AcelRx Pharmaceuticals in the fourth quarter worth about $89,000. Norges Bank purchased a new position in shares of AcelRx Pharmaceuticals in the fourth quarter worth about $578,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of AcelRx Pharmaceuticals in the first quarter worth about $140,000. Finally, Geode Capital Management LLC increased its holdings in shares of AcelRx Pharmaceuticals by 38.2% in the fourth quarter. Geode Capital Management LLC now owns 478,349 shares of the specialty pharmaceutical company’s stock worth $1,104,000 after buying an additional 132,252 shares during the period. Institutional investors and hedge funds own 15.53% of the company’s stock.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.